Roche taps new local CEO
Roche Diagnostics named a new CEO for its North American operations Tuesday to replace Michael Tillmann, who resigned on Friday.
Health Care Businesses
Articles
Tillmann out as Roche Diagnostics CEO
The management change comes as the Indianapolis company’s diabetes market share has been sliding. Roche says successor will
be named “shortly.”
Hill-Rom hires new CEO
John J. Greisch was most recently president of international operations at Baxter International Inc.
FDA cancels meeting to review Lilly’s Cymbalta
The agency said the meeting was canceled “to allow time for the FDA to review new information” about a proposed new use for
the drug.
Health care software firm RealMed regains momentum
RealMed enjoys a nearly 99-percent renewal rate among its current customers and attracted 4,000 new doctors
in 2009. Employment at the company is rising after a steady decline.
Corporations bet on insiders to bend reform
Indianapolis health care heavyweights are among those spending $635 million, employing 166 former aides to key congressional
leaders and committees in health reform process.
To keep sales force busy, Lilly takes on new drug
Eli Lilly and Co. has bought the rights to co-market a new cholesterol-fighting drug in the U.S., giving it a third heart drug for sales personnel
to push.
Health care industry braces for reform
Congress is on the cusp of transforming health insurance—if it can pass a health reform bill that was losing popularity
late in the year.
Setbacks in diabetes market batter Roche
Roche Diagnostics Corp., once the darling of the U.S. diabetes-device market, is now licking its wounds. And
it’s mulling whether to keep fighting on all fronts or to pull back.
First Indiana Future Fund off to a slow start
More than half of the venture capital fund’s original investors took a pass on its $58 million successor, the newly launched
INext.
Senate rejects drug-importation proposal
The U.S. Senate voted down a plan Tuesday to allow Americans to import prescriptions from abroad, handing drug makers
such as Indianapolis-based Eli Lilly and Co. a victory.
Lilly wins approval for long-acting Zyprexa
Once-a-month injection of best-selling drug will have patents that could extend until 2018.
Eli Lilly’s shares slip after it forecasts mixed profits in coming years
The Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results
could fall precipitously.
Lilly launching new venture capital fund
The fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly’s drug pipeline.
Lilly forecasts growth in earnings next year
Eli Lilly and Co. said it still expects its earnings per share to grow in the double-digit range through 2011.
Company’s medical device earns expedited review
FAST Diagnostics LLC said initial human trials on its method to measure kidney function faster and more accurately than existing
techniques could begin as early as next year, with commercialization following by 2012.
Ariad asks court to restore patent-suit win against Lilly
A federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent
claim.
Part of Mississippi’s Zyprexa case against Lilly dismissed
Indianapolis-based Eli Lilly and Co. has won a bid to dismiss part of a negligence lawsuit brought by Mississippi that alleges
improper marketing of antipsychotic drug Zyprexa for unapproved uses.
Lilly extends research pact with India firm
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five
years.
Lilly’s Cymbalta wins new approval for anxiety disorder
FDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.